Fifth Lane Capital, LP Neu Base Therapeutics, Inc. Transaction History

Fifth Lane Capital, LP

  • $37.3 Million
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022
SELL
$1.26 - $2.95 $25,200 - $59,000
-20,000 Closed
0 $0
Q4 2021

Feb 14, 2022
BUY
$2.6 - $4.18 $52,000 - $83,600
20,000 New
20,000 $56,000

About NeuBase Therapeutics, Inc.

NBSE Quotes by TradingView
  • Ticker NBSE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,258,700
  • Description
  • NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...
More about NBSE
Track This Portfolio

Track Fifth Lane Capital, LP Portfolio

Follow Fifth Lane Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fifth Lane Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Fifth Lane Capital, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email